Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on March 9, 2026. The filing was submitted on March 10, 2026. The Company is a global biopharma company headquartered in London, England.
Key Financial Metrics and Transaction Details
The filing details a share repurchase executed under an existing buyback programme via a non-discretionary agreement with BNP Paribas SA.
- Shares Purchased: 516,000 ordinary shares of 31¼ pence each.
- Price Range: Lowest price paid was 1,989.00p; highest price paid was 2,047.00p.
- Volume-Weighted Average Price (VWAP): 2,028.51p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON.
- Treasury Share Holdings: Following this purchase, the Company holds 247,563,094 ordinary shares in treasury.
- Shares in Issue: 4,068,605,728 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.08% of total voting rights.
Material Changes and Programme Progress
This transaction is part of a broader buyback programme announced on February 17, 2026. Since the commencement of this specific agreement on February 17, 2026, the Company has purchased an aggregate of 7,672,000 ordinary shares. The filing does not provide comparative financial data (revenue, profit, cash flow) as it is a transaction report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 17, 2026 (stated as 7,672,000).
- Confirm the current percentage of voting rights held in treasury (stated as 6.08%).
- Review the "Risk Factors" section in the 2025 Form 20-F for details on uncertainties affecting forward-looking statements.
- Check the total number of ordinary shares in issue (4,068,605,728) for denominator calculations regarding shareholder interest notifications.